The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis. (26th November 2017)

• Record Type: Journal Article
• Authors: Zhang, Junxia; Chao, Liqin; Liu, Xianghua; Shi, Yanmei; Zhang, Caili; Kong, Lingfei; Li, Ruiqin
• Is Part Of: Experimental lung research. Volume 43:Number 9/10(2017)
• Page Start: 359
• Page End: 369
• Publication Date: 2017-11-26
• Subjects: Apigenin -- polymer carrier -- idiopathic pulmonary fibrosis (IPF); Lungs -- Periodicals; Lungs -- Diseases -- Periodicals; Lung Diseases; Lung -- physiology; Respiratory System; 616.24
• DOI: 10.1080/01902148.2017.1380086
• Languages: English
• ISSNs: 0190-2148

Abstract

ABSTRACT: Aim : The capability of reducing fibrotic and inflammatory responses in lung tissues represents a gold standard for evaluating the efficacy of therapeutic interventions for treating idiopathic pulmonary fibrosis (IPF). A wide variety of therapeutic strategies have been employed in clinic to treat PF, but limited success has been obtained. Apigenin (4, 5, 7-trihydroxyflavone) is a member of flavonoid family that exerts anti-inflammatory and anti-fibrosis effects. In this study, we explore the potential therapeutic effect of apigenin in lung fibrosis. Materials and Methods : Apigenin was employed to treat IPF in a bleomycin-induced PF rat model. Apigenin was loaded onto a biodegradable polymer carrier (nanoparticle, NP) to improve its bio-solubility and bio-availability. The properties (e.g. size, apigenin loading and release profile) of the apigenin loaded polymer carrier were well-characterized. In vitro study was performed to assess the impact of apigenin on pulmonary cell viability, growth, as well as inflammatory and pro-fibrosis responses in pulmonary cells. The impact of apigenin on the production of inflammatory cytokines (e.g. TGF-β, TNF-α) and pro-fibrosis factors in bronchoalveolar lavage fluid and pulmonary cells from lung tissues was also investigated. Results : Our results showed, apigenin has anti-fibrosis effect by inhibition fibrosis related cytokines expression. And compared with apigenin in soluble form, the strategic release of apigenin is more effective in inhibiting pulmonary fibrosis and inflammation. Conclusion : Our finding suggested that apigenin loaded on polymeric carrier might be an effective treatment for pulmonary fibrosis patients.